# US 2026/0265737 A1 · Cyclic-disulfide modified phosphate based oligonucleotide prodrugs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0265737 A1
- Document ID: US20260265737A1
- Status: Published application
- Kind: A1
- Application number: 18/877,507
- Filed: 2023-06-30
- Published: 2026-09-10
- Earliest claimed: 2022-06-30
- Assignees: Alnylam Pharmaceuticals, Inc.
- Applicants: Alnylam Pharmaceuticals, Inc.
- Inventors: Alexander V. KEL'IN; Justin M. PIERSON; Jayaprakash K. NAIR; Cheng TANG; Patrick MILLER; Punit SETH
- Web page: https://patentgrep.com/patent/US20260265737A1

## CPC

- C07H 21/02: with ribosyl as saccharide radical
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C07F 9/6553: having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms
- C07F 9/655345: {the sulfur atom being part of a five-membered ring}
- C07F 9/655354: {condensed with carbocyclic rings or carbocyclic ring systems}
- C07F 9/655363: {the sulfur atom being part of a six-membered ring}
- C07F 9/65539: {condensed with carbocyclic rings or carbocyclic ring systems}
- C07F 9/6558: containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F 9/65586: {at least one of the hetero rings does not contain nitrogen as ring hetero atom}
- C07F 9/6561: containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F 9/65616: {containing the ring system [IMAGE cpc-sch-C07F-1006.gif] having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs}
- C07H 21/04: with deoxyribosyl as saccharide radical
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/322: 2'-R Modification
- C12N 2310/323: modified ring structure
- C12N 2310/3231: having an additional ring, e.g. LNA, ENA
- C12N 2310/3233: Morpholino-type ring
- C12N 2310/332: Abasic residue
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

This invention relates to a compound comprising a structure of formula (I): cyclic disulfide moiety—phosphorus coupling group (I). The cyclic disulfide moiety has the structure of: (C-I), (C-IIa)), (C-IIb), or (C-III). This invention also relates to an oligonucleotide comprising one or more compounds that comprise the structure of formula (I), wherein at least one phosphorus coupling group contains a nucleoside or oligonucleotide. The invention also relates to a pharmaceutical composition comprising the oligonucleotide described herein and a method of reducing or inhibiting the expression of a target gene by administering to the subject a therapeutically effective amount of the oligonucleotide described herein.

## Claims

### Claim 1

A compound comprising a structure of formula (I), or a salt or stereoisomer thereof:
wherein the
has the structure of:
wherein:
R1 is O or S, and is bonded to the P atom of the
R2, R4, R6, R7, R8, and R9 are each independently H, halo, CN or alkylene-CN, C(O)OR13 or alkylene-C(O)OR13, S(O)OR13 or alkylene-S(O)OR13, C(O)N(R′)(R″) or alkylene-C(O)N(R′)(R″), OR13 or alkylene-OR13, N(R′)(R″) or alkylene-N(R′)(R″), alkyl, C(R14)(R15)(R16) or alkylene-C(R14)(R15)(R16), alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, each of which can be optionally substituted by one or more Rsub groups;
R3 and R5 are each independently H, halo, CN or alkylene-CN, C(O)OR13 or alkylene-C(O)OR13, S(O)OR13 or alkylene-S(O)OR13, C(O)N(R′)(R″) or alkylene-C(O)N(R′)(R″), OR13 or alkylene-OR13, N(R′)(R″) or alkylene-N(R′)(R″), alkyl, C(R14)(R15)(R16) or alkylene-C(R14)(R15)(R16), alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, each of which can be optionally substituted by one or more Rsub groups; or R3 and R5, together with the adjacent carbon atoms and the two sulfur atoms, form a second ring;
R2 and R3, together with the adjacent carbon atom, can form another ring;
R4 and R5, together with the adjacent carbon atom, can form another ring;
R6 and R7, together with the adjacent carbon atom, can form another ring;
R8 and R9, together with the adjacent carbon atoms, can form another ring;
two or more of R2, R3, R4, R5, R6, R7, R8, R9, R14, and R15, together with the adjacent carbon atoms can form one or more rings fused with the ring containing the two sulfur atoms;
G is O, N(R′), S, or C(R14)(R15);
n is an integer of 0-6;
R13 is independently for each occurrence H, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, aralkyl, ω-amino alkyl, ω-hydroxy alkyl, ω-hydroxy alkenyl, alkylcarbonyl, or arylcarbonyl, each of which can be optionally substituted with one or more Rsub groups;
R14, R15, and R16 are each independently H, halo, haloalkyl, alkyl, alkaryl, aryl, heteroaryl, aralkyl, hydroxy, alkyloxy, aryloxy, N(R′)(R″);
R′ and R″ are each independently H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, hydroxy, alkyloxy, ω-amino alkyl, ω-hydroxy alkyl, ω-hydroxy alkenyl, or ω-hydroxy alkynyl, each of which can be optionally substituted with one or more Rsub groups; or R′ and R″, together with the adjacent nitrogen atom, form a ring, and
Rsub is independently for each occurrence halo, haloalkyl, alkyl, alkaryl, aryl, aralkyl, hydroxy, alkyloxy, aryloxy, oxo, nitro, amino, acylamino, alkylcarbamoyl, arylcarbamoyl, alkylamino, aminoalkyl, alkoxycarbonyl, carboxy, hydroxyalkyl, alkanesulfonyl, arenesulfonyl, alkanesulfonamido, arenesulfonamido, aralkylsulfonamido, alkylcarbonyl, arylcarbonyl, acyloxy, cyano, or ureido.

### Claim 2 (depends on 1)

The compound of claim 1, wherein in the
R1 is O;
G is CH2;
n is 0 or 1;
R2, R4, R6, R7, R8, and R9 are each independently H, halo, CN or C1-C6 alkylene-CN, C(O)OR13 or C1-C6 alkylene-C(O)OR13, S(O)OR13 or C1-C6 alkylene-S(O)OR13, C(O)N(R′)(R″) or C1-C6 alkylene-C(O)N(R′)(R″), OR13 or C1-C6 alkylene-OR13, N(R′)(R″) or C1-C6 alkylene-N(R′)(R″), C1-C6 alkyl, aryl, heteroaryl, each of which can be optionally substituted by one or more Rsub groups;
R3 and R5 are each independently H, halo, CN or C1-C6 alkylene-CN, C(O)OR13 or C1-C6 alkylene-C(O)OR13, S(O)OR13 or C1-C6 alkylene-S(O)OR13, C(O)N(R′)(R″) or C1-C6 alkylene-C(O)N(R′)(R″), OR13 or C1-C6 alkylene-OR13, N(R′)(R″) or C1-C6 alkylene-N(R′)(R″), C1-C6 alkyl, aryl, heteroaryl, each of which can be optionally substituted by one or more Rsub groups; or R3 and R5, together with the adjacent carbon atoms and the two sulfur atoms, form a second ring of 6-8 atoms;
R2 and R3, together with the adjacent carbon atom, can form another ring of 3-7 atoms;
R4 and R5, together with the adjacent carbon atom, can form another ring of 3-7 atoms;
R6 and R7, together with the adjacent carbon atom, can form another ring of 3-7 atoms;
R8 and R9, together with the adjacent carbon atom, can form another ring of 3-7 atoms;
two or more of R2, R3, R4, R5, R6, R7, R8, R9, R14, and R15, together with the adjacent carbon atoms can form one or more ring of 5-7 atoms fused with the ring containing the two sulfur atoms;
R13 is independently for each occurrence H, C1-C6 alkyl, aryl, alkylcarbonyl, or arylcarbonyl; and
R′ and R″ are each independently H or C1-C6 alkyl.

### Claim at position 3

3-10. (canceled)

### Claim 11 (depends on 1)

The compound of claim 1, wherein the
has the structure of:
wherein n is 1 to 4.

### Claim 12 (depends on 11)

The compound of claim 11, wherein:
R2 and R3 are each independently H, C1-6 alkyl, aryl, heteroaryl, CN or CH2CN, OR13 or CH2OR13, C(O)OR13 or CH2C(O)OR13, S(O)OR13 or CH2S(O)OR13, C(O)N(R′)(R″) or CH2C(O)N(R′)(R″), or C(R14)(R15)(R16) or CH2C(R14)(R15)(R16), each of which can be optionally substituted by one or more Rsub groups;
R13 is independently for each occurrence H, C1-6 alkyl, cycloalkyl, aryl, heteroaryl, or aralkyl;
R14, R15, and R16 are each independently H, halo, C1-6 alkyl, alkaryl, aryl, or heteroaryl; and
R′ and R″ are each independently HK C1-6 alkyl, aryl, or heteroaryl.

### Claim 13 (depends on 11)

The compound of claim 11, wherein the
has one of the following structures:

### Claim at position 7

14-17. (canceled)

### Claim 18 (depends on 1)

The compound of claim 1, wherein the
has the structure of:
wherein:
X1 and Z1 are each independently H, OH, OM, OR13, SH, SM, SR13, C(O)H, S(O)H, or alkyl, each of which can be optionally substituted with one or more Rsub groups, N(R′)(R″), NSO2R′, N═CN(R′)(R″), B(R13)3, BH3−, Se; or D-Q, wherein D is independently for each occurrence absent, O, S, N(R′), alkylene, each of which can be optionally substituted with one or more Rsub groups, and Q is independently for each occurrence a nucleoside or oligonucleotide;
X2 and Z2 are each independently N(R′)(R″), OR18, or D-Q, wherein D is independently for each occurrence absent, O, S, N, N(R′), alkylene, each of which can be optionally substituted with one or more Rsub groups, and Q is independently for each occurrence a nucleoside or oligonucleotide,
Y1 is S, O, or N(R′);
M is an organic or inorganic cation; and
R18 is H or alkyl, optionally substituted with one or more Rsub groups.

### Claim at position 9

19-20. (canceled)

### Claim 21 (depends on 18)

The compound of claim 18, wherein the
has one of the following structures:

### Claim at position 11

22-25. (canceled)

### Claim 26 (depends on 1)

The compound of claim 1, wherein the compound has one of the following structures:

### Claim at position 13

27-29. (canceled)

### Claim 30 (depends on 1)

The compound of claim 1, wherein one or more ligands are connected to any one of R2, R3, R4, R5, R6, R7, R8, and R9 of the
optionally via one or more linkers.

### Claim 31

(canceled)

### Claim 32

An oligonucleotide comprising one or more structures of formula (II):
wherein the
has the structure of:
or a salt or stereoisomer thereof,
wherein:
* represents the bond to the oligonucleotide,
Y is absent, N(R′), =O, or =S, X is —OH, —SH, C(O)H, S(O)H, alkyl optionally substituted with one or more Rsub groups, N(R′)(R″), NSO2R′, N═CN(R′)(R″), B(R13)3, BH3−, or X′, wherein X′ is N(R′)(R″), —OR2 or —SR13;
R1 is O or S, and is bonded to the P atom of the —P(Y)(X)—* group;
R2, R4, R6, R7, R8, and R9 are each independently H, halo, CN or alkylene-CN, C(O)OR13 or alkylene-C(O)OR13, S(O)OR13 or alkylene-S(O)OR13, C(O)N(R′)(R″) or alkylene-C(O)N(R′)(R″), OR13 or alkylene-OR13, N(R′)(R″) or alkylene-N(R′)(R″), alkyl, C(R14)(R15)(R16) or alkylene-C(R14)(R15)(R16), alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, each of which can be optionally substituted by one or more Rsub groups;
R3 and R5 are each independently H, halo, CN or alkylene-CN, C(O)OR13 or alkylene-C(O)OR13, S(O)OR13 or alkylene-S(O)OR13, C(O)N(R′)(R″) or alkylene-C(O)N(R′)(R″), OR13 or alkylene-OR13, N(R′)(R″) or alkylene-N(R′)(R″), alkyl, C(R14)(R15)(R16) or alkylene-C(R14)(R15)(R16), alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, each of which can be optionally substituted by one or more Rsub groups; or R3 and R5, together with the adjacent carbon atoms and the two sulfur atoms, form a second ring;
R2 and R3, together with the adjacent carbon atom, can form another ring;
R4 and R5, together with the adjacent carbon atom, can form another ring;
R6 and R7, together with the adjacent carbon atom, can form another ring;
R8 and R9, together with the adjacent carbon atoms, can form another ring;
two or more of R2, R3, R4, R5, R6, R7, R8, R9, R14, and R15, together with the adjacent carbon atoms can form one or more rings fused with the ring containing the two sulfur atoms;
G is O, N(R′), S, or C(R14)(R15);
n is an integer of 0-6;
R13 is independently for each occurrence H, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, aralkyl, ω-amino alkyl, ω-hydroxy alkyl, ω-hydroxy alkenyl, alkylcarbonyl, or arylcarbonyl, each of which can be optionally substituted with one or more Rsub groups;
R14, R15, and R16 are each independently H, halo, haloalkyl, alkyl, alkaryl, aryl, heteroaryl, aralkyl, hydroxy, alkyloxy, aryloxy, N(R′)(R″);
R′ and R″ are each independently H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, hydroxy, alkyloxy, ω-amino alkyl, ω-hydroxy alkyl, ω-hydroxy alkenyl, or ω-hydroxy alkynyl, each of which can be optionally substituted with one or more Rsub groups; or R′ and R″, together with the adjacent nitrogen atom, form a ring, and
Rsub is independently for each occurrence halo, haloalkyl, alkyl, alkaryl, aryl, aralkyl, hydroxy, alkyloxy, aryloxy, oxo, nitro, amino, acylamino, alkylcarbamoyl, arylcarbamoyl, alkylamino, aminoalkyl, alkoxycarbonyl, carboxy, hydroxyalkyl, alkanesulfonyl, arenesulfonyl, alkanesulfonamido, arenesulfonamido, aralkylsulfonamido, alkylcarbonyl, arylcarbonyl, acyloxy, cyano, or ureido;
wherein, when the
has the structure of formula (C-III), at least on
is connected at the 5′ end of the nucleoside or oligonucleotide.

### Claim at position 17

33-37. (canceled)

### Claim 38 (depends on 32)

The oligonucleotide of claim 32, comprising a structure having the formula:
or a salt thereof.

### Claim 39 (depends on 38)

The oligonucleotide of claim 38, comprising a structure having one of the following formulas:

### Claim at position 20

40-42. (canceled)

### Claim 43 (depends on 32)

The oligonucleotide of claim 32, wherein the oligonucleotide contains at least one
at the 5′-end of the oligonucleotide, and wherein the first nucleotide at the 5′-end of the oligonucleotide has the structure of
or a salt or a stereoisomer thereof, wherein:
RS is the
X is —OH, —SH, C(O)H, S(O)H, alkyl optionally substituted with one or more Rsub groups, N(R′)(R″), NSO2R′, N═CN(R′)(R″), B(R13)3, BH3−, or X′, wherein X′ is N(R′)(R″), —OR13 or —SR13
Y is S, O, or N(R′);
Z is O, S, N(R′), or CH2; and
Modified sugar is a sugar moiety containing one or more sugar modifications selected from the group consisting of 2′-modification, LNA, isomeric modification, 5′-modification, unnatural cyclic modification, acyclic modification, and abasic modification.

### Claim 44 (depends on 43)

The oligonucleotide of claim 43, wherein the sugar modification is 2′-modification, LNA, isomeric modification, 5′-modification, or abasic modification, and wherein the first nucleotide at the 5′-end of the oligonucleotide has the structure of
or a salt or a stereoisomer thereof, wherein:
* represents a bond to the subsequent optionally modified internucleotide linkage;
B is an optionally modified nucleobase, or H;
RS is the
and
R1 is H, OH, O-methoxyalkyl, O-methyl, O-allyl, CH2-allyl, fluoro, O-N-methylacetamido (O-NMA), O-N-alkylacetamido, O-dimethoxypropyl, O-dimethylaminoethoxyethyl (O-DMAEOE), O-aminopropyl (O-AP), or ara-F; or R1 forms a bridge with the 4′ carbon of the ribose sugar;
R2 is H, alkyl, or aryl;
X is —OH, —SH, C(O)H, S(O)H, alkyl optionally substituted with one or more Rsub groups, N(R′)(R″), NSO2R′, N═CN(R′)(R″), B(R13)3, BH3−, or X′, wherein X′ is N(R′)(R″), —OR13 or —SR13
Y is S, O, or N(R′);
Z is O, S, N(R′), or CH2; and
Q is O, S, CH2, or N(R′).

### Claim 45 (depends on 44)

The oligonucleotide of claim 44, wherein the first nucleotide at the 5′-end of the oligonucleotide has one of the following structures selected from groups (i)-(v):

### Claim at position 24

46-49. (canceled)

### Claim 50 (depends on 43)

The oligonucleotide of claim 43, wherein the
contains (a) unnatural cyclic modification having one of the following structures:
wherein:
* represents a bond to the subsequent optionally modified internucleotide linkage; and
B is an optionally modified nucleobase, or H; and/or
(b) acyclic modification having one of the following structures:
wherein:
* represents a bond to the subsequent optionally modified internucleotide linkage; and
B is an optionally modified nucleobase, or H.

### Claim at position 26

51-54. (canceled)

### Claim 55 (depends on 32)

The oligonucleotide of claim 32, wherein the oligonucleotide contains at least one
at the 5′-end of the oligonucleotide, and wherein the first nucleotide at the 5′-end of the oligonucleotide has the structure:
or a salt or a stereoisomer thereof, wherein
* represents a bond to the subsequent optionally modified internucleotide linkage;
Base is an optionally modified nucleobase;
RS is the
and
R is H, OH, O-methoxyalkyl, O-methyl, O-allyl, CH2-allyl, fluoro, O-N-methylacetamido (O-NMA), O-dimethylaminoethoxyethyl (O-DMAEOE), O-aminopropyl (O-AP), or ara-F.

### Claim at position 28

56-70. (canceled)

### Claim 71 (depends on 32)

A pharmaceutical composition comprising the oligonucleotide of claim 32, and a pharmaceutically acceptable excipient.

### Claim 72 (depends on 32)

A method for reducing or inhibiting the expression of a target gene in a subject, comprising:
administering to the subject the oligonucleotide of claim 32, in an amount sufficient to inhibit expression of the target gene.

### Claim at position 31

73-78. (canceled)

### Claim 79

A precursor compound comprising a structure of formula (I), or a salt or stereoisomer thereof:
wherein the
has the structure of:
wherein:
R1 is O or S, and is bonded to the P atom of the
R2 is (CH2)s—W, (CH2)s—O—(CH2)s—W, (CH2)s—(CH2CH2O)t—(CH2)s—W, or (CH2)sO(CH2CH2O)t—(CH2)s—W;
s is an integer of 0-22,
t is an integer of 1-20;
W is a reactive group;
R4 and R5 are each independently H, halo, CN or alkylene-CN, C(O)OR13 or alkylene-C(O)OR13, S(O)OR13 or alkylene-S(O)OR13, C(O)N(R′)(R″) or alkylene-C(O)N(R′)(R″), OR13 or alkylene-OR13, N(R′)(R″) or alkylene-N(R′)(R″), alkyl, C(R14)(R15)(R16) or alkylene-C(R14)(R15)(R16), alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, each of which can be optionally substituted by one or more Rsub groups; or R4 and R5 form a second ring;
G is O, N(R′), S, or C(R4)(R1)
n is an integer of 0-6;
R13 is independently for each occurrence H, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, aralkyl, ω-amino alkyl, ω-hydroxy alkyl, ω-hydroxy alkenyl, alkylcarbonyl, or arylcarbonyl, each of which can be optionally substituted with one or more Rsub groups;
R14, R15, and R16 are each independently H, halo, haloalkyl, alkyl, alkaryl, aryl, heteroaryl, aralkyl, hydroxy, alkyloxy, aryloxy, N(R′)(R″);
R′ and R″ are each independently H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, hydroxy, alkyloxy, ω-amino alkyl, ω-hydroxy alkyl, ω-hydroxy alkenyl, or ω-hydroxy alkynyl, each of which can be optionally substituted with one or more Rsub groups; or R′ and R″, together with the adjacent nitrogen atom, form a ring; and
Rsub is independently for each occurrence halo, haloalkyl, alkyl, alkaryl, aryl, aralkyl, hydroxy, alkyloxy, aryloxy, oxo, nitro, amino, acylamino, alkylcarbamoyl, arylcarbamoyl, alkylamino, aminoalkyl, alkoxycarbonyl, carboxy, hydroxyalkyl, alkanesulfonyl, arenesulfonyl, alkanesulfonamido, arenesulfonamido, aralkylsulfonamido, alkylcarbonyl, arylcarbonyl, acyloxy, cyano, or ureido.

### Claim 80 (depends on 79)

The precursor compound of claim 79, wherein the
has the structure of:
wherein R4 and R5 are each independently H, C1-6 alkyl, or phenyl; or R4 and R5, together with the adjacent carbon atom, form a second ring of 3-7 atoms.

### Claim at position 34

81-83. (canceled)

### Claim 84 (depends on 79)

The precursor compound of claim 79, wherein W in R2 is NHTFA, N3, C≡CH, C(O)OR13, or OC(O)R13, wherein R13 is C1-C3 alkyl.

### Claim 85

(canceled)

### Claim 86 (depends on 79)

The precursor compound of claim 79, wherein the
has the structure of:
wherein:
X1 and Z1 are each independently H, OH, OM, OR13, SH, SM, SR13, C(O)H, S(O)H, or alkyl, each of which can be optionally substituted with one or more Rsub groups, N(R′)(R″), NSO2R′, B(R13)3, BH3−, Se; or D-Q, wherein D is independently for each occurrence absent, 0, S, N(R′), alkylene, each of which can be optionally substituted with one or more Rsub groups, and Q is independently for each occurrence a nucleoside or oligonucleotide;
X2 and Z2 are each independently N(R′)(R″), OR18, or D-Q, wherein D is independently for each occurrence absent, O, S, N, N(R′), alkylene, each of which can be optionally substituted with one or more Rsub groups, and Q is independently for each occurrence a nucleoside or oligonucleotide,
Y1 is S, O, or N(R′);
M is an organic or inorganic cation; and
R18 is H or alkyl, optionally substituted with one or more Rsub groups.

### Claim at position 38

87-90. (canceled)

### Claim 91

An oligonucleotide comprising one or more structures of formula (II):
wherein the
has the structure of:
or a salt or stereoisomer thereof,
wherein:
* represents the bond to the oligonucleotide,
Y is absent, N(R′), =O, or =S, X is —OH, —SH, C(O)H, S(O)H, alkyl optionally substituted with one or more Rsub groups, N(R′)(R″), NSO2R′, N═CN(R′)(R″), B(R13)3, BH3−, or X′, wherein X′ is N(R′)(R″), —OR13 or —SR3;
R1 is O or S, and is bonded to the P atom of the —P(Y)(X)—* group;
R2 is (CH2)s—W, (CH2)s—O—(CH2)s—W, (CH2)s—(CH2CH2O)t—(CH2)s—W, or (CH2)sO(CH2CH2O)t—(CH2)s—W;
s is an integer of 0-22,
t is an integer of 1-20;
W is a reactive group;
R4 and R5 are each independently H, halo, CN or alkylene-CN, C(O)OR13 or alkylene-C(O)OR13, S(O)OR13 or alkylene-S(O)OR13, C(O)N(R′)(R″) or alkylene-C(O)N(R′)(R″), OR13 or alkylene-OR13, N(R′)(R″) or alkylene-N(R′)(R″), alkyl, C(R14)(R15)(R16) or alkylene-C(R14)(R15)(R16), alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, each of which can be optionally substituted by one or more Rsub groups; or R4 and R5 form a second ring;
G is O, N(R′), S, or C(R14)(R15);
n is an integer of 0-6;
R13 is independently for each occurrence H, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, aralkyl, ω-amino alkyl, ω-hydroxy alkyl, ω-hydroxy alkenyl, alkylcarbonyl, or arylcarbonyl, each of which can be optionally substituted with one or more Rsub groups;
R14, R15, and R16 are each independently H, halo, haloalkyl, alkyl, alkaryl, aryl, heteroaryl, aralkyl, hydroxy, alkyloxy, aryloxy, N(R′)(R″);
R′ and R″ are each independently H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, hydroxy, alkyloxy, ω-amino alkyl, ω-hydroxy alkyl, ω-hydroxy alkenyl, or ω-hydroxy alkynyl, each of which can be optionally substituted with one or more Rsub groups; or R′ and R″ together with the adjacent nitrogen atom form a ring, and
Rsub is independently for each occurrence halo, haloalkyl, alkyl, alkaryl, aryl, aralkyl, hydroxy, alkyloxy, aryloxy, oxo, nitro, amino, acylamino, alkylcarbamoyl, arylcarbamoyl, alkylamino, aminoalkyl, alkoxycarbonyl, carboxy, hydroxyalkyl, alkanesulfonyl, arenesulfonyl, alkanesulfonamido, arenesulfonamido, aralkylsulfonamido, alkylcarbonyl, arylcarbonyl, acyloxy, cyano, or ureido;
wherein at least one
is connected at the 5′ end of the nucleoside or oligonucleotide.

### Claim 92 (depends on 91)

The oligonucleotide of claim 91, wherein the
has the structure of:
wherein R4 and R5 are each independently H, C1-6 alkyl, or phenyl; or R4 and R5, together with the adjacent carbon atom, form a second ring of 3-7 atoms.

### Claim at position 41

93-95. (canceled)

### Claim 96 (depends on 91)

The oligonucleotide of claim 91, wherein W in R2 is NHTFA, N3, C≡CH, C(O)OR13, OC(O)R13, wherein R13 is C1-C3 alkyl.

### Claim at position 43

97-98. (canceled)
